Lantus package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Lantus (Insulin Glargine)

Lantus Solostar Pen

Insulin Glargine

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Lantus (insulin glargine) is a long-acting insulin listed in our Long-acting insulin and Insulin directories and prescribed for blood glucose control in diabetes (1.1) (2.1). Administered via the subcutaneous route, Lantus is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Lantus is a medication containing the active pharmaceutical ingredient insulin glargine, classified pharmacologically as a long-acting insulin (2.1). It is clinically indicated for the management of blood glucose control in diabetes as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Long-acting insulin section of our catalogue, patients and prescribers frequently review Lantus alongside related therapies such as Basaglar Kwikpen & Cartridges (Insulin Glargine), Semglee (Insulin Glargine), Soliqua (Insulin Glargine), and Toujeo (Insulin Glargine).

Official Indications and Usage

Lantus is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Limitations of use: Not recommended for the treatment of diabetic ketoacidosis. (1.1)

Mechanism of Action and Pharmacology

The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis. (1.1) (3.1)

What is Type 1 diabetes?

Type 1 diabetes develops when the body makes little or no insulin. Insulin treatment replaces a hormone needed to manage blood glucose. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Type 1 diabetes condition guide for appointment questions and related therapies (4.1).

What is Type 2 diabetes?

Type 2 diabetes involves high blood glucose because the body does not use insulin effectively and may not make enough. Treatment depends on individual glucose, heart, kidney, and other health needs. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Type 2 diabetes condition guide for appointment questions and related therapies (4.1).

Ordering Lantus from Canada for U.S. Delivery

U.S. patients can order Lantus (Insulin Glargine) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$29.99 USD Cold-Chain Cooler

  • Packed in an insulated thermal cooler with gel packs and temperature indicators for $29.99 USD.
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Lantus
Chemical / Generic Name Insulin Glargine
Pharmacological Class Long-acting insulin
Therapeutic Category Insulin · Long-acting insulin
Same-Ingredient Catalogue Entries Basaglar Kwikpen & Cartridges (Insulin Glargine), Semglee (Insulin Glargine), Soliqua (Insulin Glargine), Toujeo (Insulin Glargine)
Molecular Formula C267H404N72O78S6 (3.1)
Molecular Weight 6063 g/mol (3.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NIH PubChem, NLM MedlinePlus
Routes of Administration Subcutaneous
Available Dosage Strengths 100u/mL, 100u/mL/10mL
Dosage Form Solution
Primary Indications Blood Glucose Control In Diabetes
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
PubChem CID 118984454
FDA UNII Identifier 2ZM8CX04RZ
NLM RxNorm Concept ID (RxCUI) 285018, 311041, 847230, 847232
FDA Application License BLA021081
Official DailyMed SetID d5e07a0c-7e14-4756-9152-9fea485d654a
Catalogue Index Links Letter L Index · All Medications · All Categories

Directions

Dosage and Administration Overview

Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. Do not dilute or mix with any other insulin or solution. Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. (1.1)

Presentations and Strengths

Injection: 100 units/mL (U-100) a clear and colorless solution available as: 10 mL multiple-dose vial 3 mL single-patient-use Lantus SoloStar prefilled pen Injection: 100 units/mL (U-100) available as: 10 mL multiple-dose vial 3 mL single-patient-use SoloStar prefilled pen. (1.1)

Administration Guidance

Lantus is administered by injection according to your prescriber’s individualized dosing schedule (1.1). Always verify the concentration, pen or vial presentation, and dose markings prior to administration, rotate injection sites as instructed, and never share injection pens, needles, or cartridges between patients.

Missed Dose Guidance

If you miss a scheduled dose of Lantus, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Lantus is insulin glargine (molecular formula C267H404N72O78S6, molecular weight 6063 g/mol) (1.1) (3.1). Other catalogue entries containing insulin glargine include Basaglar Kwikpen & Cartridges (Insulin Glargine), Semglee (Insulin Glargine), Soliqua (Insulin Glargine), and Toujeo (Insulin Glargine).

Inactive Ingredients (Excipients)

According to the U.S. FDA product labeling, formulation excipients include glycerol 85%, m-cresol (1.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.

Cautions and important safety information

Contraindications

Lantus is contraindicated: During episodes of hypoglycemia In patients with hypersensitivity to insulin glargine or any of the excipients in Lantus During episodes of hypoglycemia Hypersensitivity to insulin glargine or any of the excipients in Lantus. (1.1)

Key Clinical Precautions

Before starting or continuing Lantus, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Heart failure: Fluid retention or cardiovascular workload changes may precipitate or worsen congestive heart failure in susceptible patients. Report sudden weight gain, shortness of breath, or ankle and leg swelling to your healthcare provider.
  • Hypoglycemia (low blood sugar): When used alongside insulin therapies or insulin secretagogues (such as sulfonylureas), the risk of hypoglycemia increases. Patients may need a lower dose of their secretagogue or insulin and should recognize symptoms like shakiness, sweating, fast heartbeat, dizziness, and confusion.
  • Hypersensitivity and anaphylaxis: Serious allergic reactions, including anaphylaxis, angioedema, and severe rash, have been reported. Discontinue use and seek immediate medical care if swelling of the face, lips, tongue, or throat or difficulty breathing occurs.
  • Seizure threshold: This medication may lower the seizure threshold or require caution in patients with a history of seizure disorders or conditions that predispose to seizures.

Pregnancy, Lactation, and Special Populations

Published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. Rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dosage of 0.2 units/kg/day. Overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin. (1.1)

Interactions

Official Drug Interaction Overview

Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics. GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when Lantus is coadministered with these drugs. (1.1)

Important Interaction Categories

Concomitant use of Lantus with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Lithium: This medication may alter renal lithium clearance, either increasing serum lithium levels (risking lithium toxicity) or decreasing lithium concentrations (reducing therapeutic efficacy). Serum lithium levels should be monitored closely when starting, adjusting, or stopping therapy.
  • Monoamine oxidase inhibitors (MAOIs, such as phenelzine, tranylcypromine, selegiline, or linezolid): Concomitant use or use within 14 days of stopping an MAOI can cause severe drug interactions, including hypertensive crisis, serotonin syndrome, or enhanced hypoglycemic and central nervous system effects.
  • Alcohol: Excessive alcohol consumption can potentiate blood-sugar fluctuations, increase the risk of lactic acidosis or ketoacidosis in metabolic therapies, heighten gastrointestinal irritation, or increase drowsiness and orthostatic dizziness.

Side effects

Like all medications, Lantus can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
  • Peripheral edema (swelling of ankles, feet, or hands): Fluid retention may occur; notify your doctor if swelling is rapid or accompanied by shortness of breath.
  • Cough or upper respiratory symptoms (nasopharyngitis): Common mild respiratory symptoms reported in clinical studies.
  • Injection- or application-site reactions: Mild redness, itching, tenderness, or bruising at the administration site; rotating injection sites as directed helps minimize local irritation.

Clinical Trial and Postmarketing Adverse Reactions

Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain. (1.1)

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Dispense in the original sealed carton with the enclosed Instructions for Use. Store unused Lantus in a refrigerator between 36°F and 46°F (2°C and 8°C). Do not freeze. Discard Lantus if it has been frozen. Protect Lantus from direct heat and light. (1.1)

Temperature-Sensitive Storage

Keep unopened packages refrigerated within the temperature range specified on the manufacturer's carton (typically 2°C to 8°C / 36°F to 46°F). Do not freeze. Once in use, follow the exact in-use storage temperature and discard calendar printed on your specific pen, vial, or cartridge leaflet (2.1).

Frequently Asked Questions About Lantus

What is Lantus and what active ingredient does it contain?

Lantus is a long-acting insulin containing the active pharmaceutical ingredient insulin glargine (chemical formula C267H404N72O78S6). It is supplied for subcutaneous administration and requires a valid prescription where applicable.

How does Lantus work in the body?

The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

What conditions is Lantus prescribed to treat?

Lantus is primarily indicated for blood glucose control in diabetes. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Lantus?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Lantus is administered via the subcutaneous route. Administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Lantus?

Commonly reported side effects of Lantus include loose stools, headache, swelling, cough, and a reaction at the treatment site. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Lantus?

Important interaction categories for Lantus include lithium, monoamine oxidase inhibitors, and alcohol. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Lantus be used during pregnancy or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Lantus to weigh the clinical benefits and potential risks.

Do I need a prescription to buy Lantus online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Lantus (Insulin Glargine) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Lantus have a generic equivalent (Insulin Glargine) at a Canada pharmacy?

Currently, Lantus (Insulin Glargine) is dispensed in our catalogue as a brand-name formulation. Check our Insulin Glargine active ingredient hub for updates as licensed generic presentations become available.

How is Lantus shipped to U.S. residents, and how much does shipping cost?

Lantus requires Cold-Chain temperature-sensitive handling at a flat rate of $29.99 USD per order. Once your prescription passes safety checks (<1 business day) and you complete the mandatory licensed pharmacist consultation (check your voicemails and text messages), Lantus is packed in a medication-specific insulated thermal cooler with cold gel packs, seasonal packaging adjustments, and temperature indicators, and shipped from Manitoba, Canada via Canada Post and USPS (3 to 7 business days) with full tracking. A physical U.S. street address (no P.O. Boxes) and signature upon delivery are required.

How can I send or transfer my Lantus prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Lantus prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Lantus (Insulin Glargine) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Lantus (insulin glargine) injection, solution Lantus SoloStar (insulin glargine) injection, solution [sanofi-aventis U.S. llc]. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-28).
  3. (3.1) PubChem Compound Summary for cid 118984454 (Insulin Glargine). National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Official regulatory & clinical reference. (Accessed 2026-10-29).
  4. (4.1) MedlinePlus Medical Encyclopedia: Diabetes Type 1. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  5. (5.1) MedlinePlus Medical Encyclopedia: Diabetes Type 2. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help